Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
lunedì, ottobre 26
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
NeoGenomics Inc
NEO
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$16.69
0.10
0.6%
Ult. Agg.: Oct 26, 4:00 PM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Utili:
I risultati del Q3 2026 saranno pubblicati domani mer ott 28th dopo la chiusura del mercato
Conference call:
La conference call è prevista per domani alle ore 4:30 PM
Clicca per vedere il webcast
NeoGenomics Financials
NeoGenomics (NEO) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
What's Going On With NeoGenomics Stock Tuesday?
NeoGenomics stock falls after leadership shuffle and Q3 preliminary results. Analysts weigh in on growth and valuation.
Vandana Singh
PRO
NeoGenomics Sees Q3 Revenue Of About $209M; Reiterates FY2026 Revenue, Adjusted EBITDA Guidance, Expects To Raise Revenue Guidance Midpoint On Q3 Call
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001077183/000107718326000069/neo-20261005.htm
Benzinga Newsdesk
PRO
NeoGenomics Raises FY2026 Sales Guidance from $797.000M-$803.000M to $802.000M-$806.000M vs $800.433M Est
NeoGenomics (NASDAQ:NEO) raises FY2026 sales outlook from $797.000 million-$803.000 million to $802.000 million-$806.000 million vs $800.433 million estimate.
Benzinga Newsdesk
PRO
NeoGenomics Q2 Adj. EPS $0.05 Beats $0.03 Estimate, Sales $202.000M Beat $196.997M Estimate
NeoGenomics (NASDAQ:NEO) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.03 by 66.67 percent. This is a 66.67 percent increase over earnings of $0.03 per share from the
Benzinga Newsdesk
Earnings Scheduled For May 12, 2026
Benzinga Insights
PRO
NeoGenomics Raises FY2026 Sales Guidance from $793.000M-$801.000M to $797.000M-$803.000M vs $796.641M Est
NeoGenomics (NASDAQ:NEO) raises FY2026 sales outlook from $793.000 million-$801.000 million to $797.000 million-$803.000 million vs $796.641 million estimate.
Benzinga Newsdesk
